The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...

Genentech Therapeutics’s Phase III trial of Itovebi in patients with certain types of metastatic breast cancer has met the gold standard oncology endpoint of overall survival (OS) while also ...

Genentech, a member of Roche (RHHBY), announced topline results from the overall survival analysis of the Phase III INAVO120 study ...

Results from the randomised, double-blind trial showed that Itovebi was able to show a benefit in overall survival. Credit: Shutterstock / NMK-Studio Genentech Therapeutics’s Phase III trial of ...

The robotics and automation industry in Germany has lost competitiveness: for 2025, it is forecasting a drop of minus 9 percent to 13.8 billion euros in total turnover. Last year, the sector closed ...

MemorialCare Saddleback Medical Center announced today that it is one of America's 250 Best Hospitals for 2025, according to ...

The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.

The Phase III INAVO120 trial found that a combination of Itovebi (inavolisib) with Ibrance (palbociclib) and Faslodex (fulvestrant) significantly improved overall survival and progression-free ...

Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Wafaa Mamilli (1967) will join the company as Chief Digital Technology Officer (CDTO), reporting to Group CEO, Thomas Schinecker ...